Literature DB >> 6525337

Sequence variation in heparin octasaccharides with high affinity for antithrombin III.

D H Atha, A W Stephens, A Rimon, R D Rosenberg.   

Abstract

We have isolated from nitrous acid cleavage products of heparin two major octasaccharide fragments which bind with high affinity to human antithrombin. Octasaccharide S, with the predominant structure iduronic acid----N-acetylglucosamine 6-O-sulfate----glucuronic acid-----N-sulfated glucosamine 3,6-di-O-sulfate----iduronic acid 2-O-sulfate----N-sulfated glucosamine 6-O-sulfate----iduronic acid 2-O-sulfate----anhydromannitol 6-O-sulfate, is sensitive to cleavage by Flavobacterium heparinase as well as platelet heparitinase and binds to antithrombin with a dissociation constant of (5-15) X 10(-8) M. Octasaccharide R, with the predominant structure iduronic acid 2-O-sulfate----N-sulfated glucosamine 6-O-sulfate----iduronic acid----N-acetylglucosamine 6-O-sulfate----glucuronic acid----N-sulfated glucosamine 3,6-di-O-sulfate----iduronic acid 2-O-sulfate----anhydromannitol 6-O-sulfate, is resistant to degradation by both enzymes and binds antithrombin with a dissociation constant of (4-18) X 10(-7) M. The occurrence of a 15-17% replacement of N-sulfated glucosamine 3,6-di-O-sulfate with N-sulfated glucosamine 3-O-sulfate and a 10-12% replacement of iduronic acid with glucuronic acid in both octasaccharides indicates that these substitutions have little or no effect on the binding of the oligosaccharides to the protease inhibitor. When bound to antithrombin, both octasaccharides produce a 40% enhancement in the intrinsic fluorescence of the protease inhibitor and a rate of human factor Xa inhibition of 5 X 10(5) M-1 s-1 as monitored by stopped-flow fluorometry. This suggests that the conformation of antithrombin in the region of the factor Xa binding site is similar when the protease inhibitor is complexed with either octasaccharide.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6525337     DOI: 10.1021/bi00319a020

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  14 in total

1.  Cell mutants defective in synthesizing a heparan sulfate proteoglycan with regions of defined monosaccharide sequence.

Authors:  A L De Agostini; H K Lau; C Leone; H Youssoufian; R D Rosenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

2.  Screening for anticoagulant heparan sulfate octasaccharides and fine structure characterization using tandem mass spectrometry.

Authors:  Hicham Naimy; Nancy Leymarie; Joseph Zaia
Journal:  Biochemistry       Date:  2010-05-04       Impact factor: 3.162

3.  Anti-thrombin activities of heparin. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin.

Authors:  B Bray; D A Lane; J M Freyssinet; G Pejler; U Lindahl
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

4.  Finding a needle in a haystack: development of a combinatorial virtual screening approach for identifying high specificity heparin/heparan sulfate sequence(s).

Authors:  Arjun Raghuraman; Philip D Mosier; Umesh R Desai
Journal:  J Med Chem       Date:  2006-06-15       Impact factor: 7.446

5.  Ex vivo model of an immobilized-enzyme reactor.

Authors:  H Bernstein; R Langer
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

6.  A fragment of antithrombin that binds both heparin and thrombin.

Authors:  L Rosenfeld; I Danishefsky
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

7.  Spatiotemporal distribution of heparan sulfate epitopes during murine cartilage growth plate development.

Authors:  Ronald R Gomes; Toin H Van Kuppevelt; Mary C Farach-Carson; Daniel D Carson
Journal:  Histochem Cell Biol       Date:  2006-07-12       Impact factor: 4.304

8.  Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation.

Authors:  A J Brown; M Alicknavitch; S S D'Souza; T Daikoku; C B Kirn-Safran; D Marchetti; D D Carson; M C Farach-Carson
Journal:  Bone       Date:  2008-06-06       Impact factor: 4.398

Review 9.  Low molecular weight heparins. An objective overview.

Authors:  D Hoppensteadt; J M Walenga; J Fareed
Journal:  Drugs Aging       Date:  1992 Sep-Oct       Impact factor: 3.923

10.  Location of antithrombin-binding regions in rat skin heparin proteoglycans.

Authors:  K G Jacobsson; U Lindahl; A A Horner
Journal:  Biochem J       Date:  1986-12-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.